HomeCompareEYEN vs VYM

EYEN vs VYM: Dividend Comparison 2026

EYEN yields 26.46% · VYM yields 2.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EYEN wins by $79.8K in total portfolio value
10 years
EYEN
EYEN
● Live price
26.46%
Share price
$7.56
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.6K
Annual income
$12,760.49
Full EYEN calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.41%
Share price
$145.48
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$278.55
Full VYM calculator →

Portfolio growth — EYEN vs VYM

📍 EYEN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEYENVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EYEN + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EYEN pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EYEN
Annual income on $10K today (after 15% tax)
$2,248.68/yr
After 10yr DRIP, annual income (after tax)
$10,846.42/yr
VYM
Annual income on $10K today (after 15% tax)
$205.23/yr
After 10yr DRIP, annual income (after tax)
$236.77/yr
At 15% tax rate, EYEN beats the other by $10,609.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EYEN + VYM for your $10,000?

EYEN: 50%VYM: 50%
100% VYM50/50100% EYEN
Portfolio after 10yr
$67.7K
Annual income
$6,519.52/yr
Blended yield
9.62%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EYEN buys
0
VYM buys
1
PoliticianChamberTickerTypeAmountDate
Carol Devine Miller🏢 House$VYM▲ Buy$15,001 - $50,0002022-11-02
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEYENVYM
Forward yield26.46%2.41%
Annual dividend / share$2.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$107.6K$27.8K
Annual income after 10y$12,760.49$278.55
Total dividends collected$69.8K$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: EYEN vs VYM ($10,000, DRIP)

YearEYEN PortfolioEYEN Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$13,346$2,645.50$11,151$241.44+$2.2KEYEN
2$17,579$3,299.59$12,413$246.79+$5.2KEYEN
3$22,872$4,062.02$13,794$251.79+$9.1KEYEN
4$29,412$4,939.21$15,306$256.47+$14.1KEYEN
5$37,407$5,936.07$16,960$260.84+$20.4KEYEN
6$47,081$7,055.73$18,768$264.92+$28.3KEYEN
7$58,676$8,299.52$20,745$268.71+$37.9KEYEN
8$72,451$9,666.86$22,905$272.24+$49.5KEYEN
9$88,677$11,155.27$25,265$275.51+$63.4KEYEN
10$107,645$12,760.49$27,842$278.55+$79.8KEYEN

EYEN vs VYM: Complete Analysis 2026

EYENStock

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

Full EYEN Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this EYEN vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EYEN vs SCHDEYEN vs JEPIEYEN vs OEYEN vs KOEYEN vs MAINEYEN vs VIGEYEN vs DGROEYEN vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.